Addus Homecare (NASDAQ:ADUS) Trading 5.6% Higher

06:46am, Thursday, 30'th Apr 2020
Addus Homecare Co. (NASDAQ:ADUS) traded up 5.6% during mid-day trading on Wednesday . The stock traded as high as $83.70 and last traded at $83.08, 149,816 shares changed hands during mid-day trading.
Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, announced today that it will release preliminary earnings for the first quarter ended March 31, 2020, on Monday, May 4, 2

Oppenheimer Believes Humana (HUM) Won't Stop Here

12:16pm, Wednesday, 29'th Apr 2020
In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Humana (HUM), with a price target of $400.00. The company's
In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Humana (HUM – Research Report), with
Aufstockung der Mittel für Fraueneinrichtungen auf 210 Millionen Euro zur Krisenbewältigung sofort notwendig
In a report released yesterday, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Community Health (CYH), with a price target of $8.00. The
In a report released yesterday, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Community Health ( CYH – Research Report ), with a price target of $8.00 . The company’s shares close
Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Chemed (CHE) yesterday and set a price target of $535.00. The company's shares closed
Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Chemed (CHE – Research Report) yesterday and set a price target
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Centene (CNC) and Moderna (MRNA) with bullish sentiments.
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Centene ( CNC – Research Report ) and Moderna ( MRNA – Research Report ) with bullish sentiments. C
Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Amedisys (AMED) today and set a price target of $215.00. The company's shares closed
Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Amedisys ( AMED – Research Report ) today and set a price target of $215.00 . The company’s shares closed last Friday at $186.50.
Bank of America Corp DE trimmed its holdings in shares of Addus Homecare Co. (NASDAQ:ADUS) by 13.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securiti
Addus Homecare (NASDAQ:ADUS)‘s stock had its “buy” rating reaffirmed by analysts at Royal Bank of Canada in a report released on Monday, AnalystRatings.com reports. They presently have a $98.00
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE